Join us for a behind-the-scenes look into how Moderna translated science into medicine, and the future for this vaccine and COVID.
Sponsored by Jason Weiner and Nicole Zatlyn, the Vilna Shul Lifesavers Speaker Series invites you to engage deeply with global thinkers, influencers and philanthropists championing social justice and positive change. These unique, intimate conversations profoundly touch those present by providing behind-the-scenes opportunities to engage with leaders that are ... view more »
Join us for a behind-the-scenes look into how Moderna translated science into medicine, and the future for this vaccine and COVID.
Sponsored by Jason Weiner and Nicole Zatlyn, the Vilna Shul Lifesavers Speaker Series invites you to engage deeply with global thinkers, influencers and philanthropists championing social justice and positive change. These unique, intimate conversations profoundly touch those present by providing behind-the-scenes opportunities to engage with leaders that are tackling important, global issues in science, art, religion, business and politics.
As Chief Medical Officer, Tal Zaks oversees clinical development and regulatory affairs across Moderna. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization. Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers. Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania. Dr. Zaks serves on the Board of Directors of Adaptimmune Therapeutics plc.
View less
